Tracers / [177Lu]Lu-vMET1-Fc
[177Lu]Lu-vMET1-Fc
Also written as [Lu-177]Lu-vMET1-Fc
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- MET-targeted shark-derived single-domain VNAR antibody (VNAR-Fc fusion) conjugated to DOTA chelate
- Target / mechanism
- Targets MET receptor tyrosine kinase PMID 41676672
- Clinical application
- Targeted beta-particle radiotherapy for MET-altered NSCLC in preclinical mouse models PMID 41676672
- Theranostic pair
- <a href="/tracers/zr89-vmet1fc/">zr89-vmet1fc</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | vMET1-Fc | 41676672 2026 bioRxiv the antibody was site-specifically radiolabeled with the beta particle-emitting radioisotope lutetium-177 (t1/2 = 6.7d) via a DOTA chelate group on the Fc domain |
Need this precursor?We can point you to suppliers for [177Lu]Lu-vMET1-Fc, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41676672. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41676672: 'the antibody was site-specifically radiolabeled with the beta particle-emitting radioisotope lutetium-177 (t1/2 = 6.7d) via a DOTA chelate group on the Fc domain'.